Genovese, Mark C http://orcid.org/0000-0001-5294-4503
van der Heijde, Désirée http://orcid.org/0000-0002-5781-158X
Lin, Yong
St John, Gregory
Wang, Sheldon
van Hoogstraten, Hubert
Gómez-Reino, Juan José
Kivitz, Alan
Maldonado-Cocco, José Antonio
Seriolo, Bruno
Stanislav, Marina
Burmester, Gerd R http://orcid.org/0000-0001-7518-1131
Clinical trials referenced in this document:
Documents that mention this clinical trial
SAT0180 Efficacy and safety of sarilumab 200 MG Q2W administered as combination therapy or monotherapy in different patient populations with active RA
https://doi.org/10.1136/annrheumdis-2017-eular.1275
FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.2181
SAT0192 Sarilumab suppresses thrombosis-related gene expression in circulating blood cells in mtx-ir and tnf-ir patients with active rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.5183
SAT0179 The ASP358ALA variant in the IL6R gene is significantly associated with differences in soluble IL-6R protein levels but not with differences in sarilumab response in rheumatoid arthritis (RA) patients
https://doi.org/10.1136/annrheumdis-2017-eular.4983
SAT0207 Depressive symptoms in patients with rheumatoid arthritis in sarilumab target and mobility trials and impact of treatment
https://doi.org/10.1136/annrheumdis-2018-eular.3723
FRI0228 Ugt1a1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab
https://doi.org/10.1136/annrheumdis-2017-eular.5016
FRI0242 Association between clinical and radiographic responses, and physical function in a phase 3 study of sarilumab plus methotrexate in patients with active, moderate-to-severe rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.3513
SAT0102 NONINFLAMMATORY PAIN IS A FREQUENT PHENOMENON IN RHEUMATOID ARTHRITIS AND RESPONDS WELL TO TREATMENT WITH SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2015
THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.1977
SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
https://doi.org/10.1136/annrheumdis-2019-eular.245
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)
https://doi.org/10.1136/annrheumdis-2013-204963
FRI0120 HIGH LEVELS OF INTERLEUKIN-6 (IL-6) IN RA PATIENTS ARE ASSOCIATED WITH GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES (PROS) FOR SARILUMAB COMPARED WITH ADALIMUMAB
https://doi.org/10.1136/annrheumdis-2019-eular.3294
SAT0172 Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csdmards in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.1373
FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS
https://doi.org/10.1136/annrheumdis-2019-eular.740
SAT0100 ASSOCIATION BETWEEN LOW HEMOGLOBIN AND RADIOGRAPHIC PROGRESSION OVER 52 WEEKS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL OF SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2008
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
https://doi.org/10.1136/rmdopen-2018-000887
Documents that mention this clinical trial
SAT0180 Efficacy and safety of sarilumab 200 MG Q2W administered as combination therapy or monotherapy in different patient populations with active RA
https://doi.org/10.1136/annrheumdis-2017-eular.1275
FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.2181
SAT0192 Sarilumab suppresses thrombosis-related gene expression in circulating blood cells in mtx-ir and tnf-ir patients with active rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.5183
SAT0179 The ASP358ALA variant in the IL6R gene is significantly associated with differences in soluble IL-6R protein levels but not with differences in sarilumab response in rheumatoid arthritis (RA) patients
https://doi.org/10.1136/annrheumdis-2017-eular.4983
SAT0207 Depressive symptoms in patients with rheumatoid arthritis in sarilumab target and mobility trials and impact of treatment
https://doi.org/10.1136/annrheumdis-2018-eular.3723
FRI0228 Ugt1a1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab
https://doi.org/10.1136/annrheumdis-2017-eular.5016
FRI0242 Association between clinical and radiographic responses, and physical function in a phase 3 study of sarilumab plus methotrexate in patients with active, moderate-to-severe rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.3513
SAT0102 NONINFLAMMATORY PAIN IS A FREQUENT PHENOMENON IN RHEUMATOID ARTHRITIS AND RESPONDS WELL TO TREATMENT WITH SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2015
SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
https://doi.org/10.1136/annrheumdis-2019-eular.245
THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.1977
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)
https://doi.org/10.1136/annrheumdis-2013-204963
SAT0172 Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csdmards in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.1373
FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS
https://doi.org/10.1136/annrheumdis-2019-eular.740
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
https://doi.org/10.1136/rmdopen-2018-000887
SAT0100 ASSOCIATION BETWEEN LOW HEMOGLOBIN AND RADIOGRAPHIC PROGRESSION OVER 52 WEEKS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL OF SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2008
FRI0120 HIGH LEVELS OF INTERLEUKIN-6 (IL-6) IN RA PATIENTS ARE ASSOCIATED WITH GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES (PROS) FOR SARILUMAB COMPARED WITH ADALIMUMAB
https://doi.org/10.1136/annrheumdis-2019-eular.3294
Documents that mention this clinical trial
SAT0212 Sarilumab dose reduction in an open-label extension study in ra patients with inadequate response to tnf inhibitors
https://doi.org/10.1136/annrheumdis-2017-eular.5155
THU0215 Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab
https://doi.org/10.1136/annrheumdis-2018-eular.1376
SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
https://doi.org/10.1136/annrheumdis-2019-eular.245
FRI0092 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TUMOR NECROSIS FACTOR INHIBITORS
https://doi.org/10.1136/annrheumdis-2020-eular.1946
SAT0172 Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csdmards in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.1373
FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS
https://doi.org/10.1136/annrheumdis-2019-eular.740
SAT0106 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH 1 OR >1 PRIOR TUMOR NECROSIS FACTOR INHIBITOR FAILURES
https://doi.org/10.1136/annrheumdis-2020-eular.332
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
https://doi.org/10.1136/rmdopen-2018-000887
Documents that mention this clinical trial
SAT0180 Efficacy and safety of sarilumab 200 MG Q2W administered as combination therapy or monotherapy in different patient populations with active RA
https://doi.org/10.1136/annrheumdis-2017-eular.1275
FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.2181
SAT0192 Sarilumab suppresses thrombosis-related gene expression in circulating blood cells in mtx-ir and tnf-ir patients with active rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.5183
SAT0179 The ASP358ALA variant in the IL6R gene is significantly associated with differences in soluble IL-6R protein levels but not with differences in sarilumab response in rheumatoid arthritis (RA) patients
https://doi.org/10.1136/annrheumdis-2017-eular.4983
SAT0207 Depressive symptoms in patients with rheumatoid arthritis in sarilumab target and mobility trials and impact of treatment
https://doi.org/10.1136/annrheumdis-2018-eular.3723
FRI0228 Ugt1a1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab
https://doi.org/10.1136/annrheumdis-2017-eular.5016
FRI0242 Association between clinical and radiographic responses, and physical function in a phase 3 study of sarilumab plus methotrexate in patients with active, moderate-to-severe rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.3513
SAT0102 NONINFLAMMATORY PAIN IS A FREQUENT PHENOMENON IN RHEUMATOID ARTHRITIS AND RESPONDS WELL TO TREATMENT WITH SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2015
SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
https://doi.org/10.1136/annrheumdis-2019-eular.245
THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.1977
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)
https://doi.org/10.1136/annrheumdis-2013-204963
FRI0120 HIGH LEVELS OF INTERLEUKIN-6 (IL-6) IN RA PATIENTS ARE ASSOCIATED WITH GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES (PROS) FOR SARILUMAB COMPARED WITH ADALIMUMAB
https://doi.org/10.1136/annrheumdis-2019-eular.3294
SAT0172 Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csdmards in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.1373
FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS
https://doi.org/10.1136/annrheumdis-2019-eular.740
SAT0100 ASSOCIATION BETWEEN LOW HEMOGLOBIN AND RADIOGRAPHIC PROGRESSION OVER 52 WEEKS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL OF SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2008
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
https://doi.org/10.1136/rmdopen-2018-000887
Documents that mention this clinical trial
SAT0180 Efficacy and safety of sarilumab 200 MG Q2W administered as combination therapy or monotherapy in different patient populations with active RA
https://doi.org/10.1136/annrheumdis-2017-eular.1275
FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.2181
SAT0192 Sarilumab suppresses thrombosis-related gene expression in circulating blood cells in mtx-ir and tnf-ir patients with active rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.5183
SAT0179 The ASP358ALA variant in the IL6R gene is significantly associated with differences in soluble IL-6R protein levels but not with differences in sarilumab response in rheumatoid arthritis (RA) patients
https://doi.org/10.1136/annrheumdis-2017-eular.4983
SAT0207 Depressive symptoms in patients with rheumatoid arthritis in sarilumab target and mobility trials and impact of treatment
https://doi.org/10.1136/annrheumdis-2018-eular.3723
FRI0228 Ugt1a1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab
https://doi.org/10.1136/annrheumdis-2017-eular.5016
FRI0242 Association between clinical and radiographic responses, and physical function in a phase 3 study of sarilumab plus methotrexate in patients with active, moderate-to-severe rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.3513
SAT0102 NONINFLAMMATORY PAIN IS A FREQUENT PHENOMENON IN RHEUMATOID ARTHRITIS AND RESPONDS WELL TO TREATMENT WITH SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2015
SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
https://doi.org/10.1136/annrheumdis-2019-eular.245
THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.1977
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)
https://doi.org/10.1136/annrheumdis-2013-204963
SAT0172 Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csdmards in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.1373
FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS
https://doi.org/10.1136/annrheumdis-2019-eular.740
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
https://doi.org/10.1136/rmdopen-2018-000887
SAT0100 ASSOCIATION BETWEEN LOW HEMOGLOBIN AND RADIOGRAPHIC PROGRESSION OVER 52 WEEKS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL OF SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2008
FRI0120 HIGH LEVELS OF INTERLEUKIN-6 (IL-6) IN RA PATIENTS ARE ASSOCIATED WITH GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES (PROS) FOR SARILUMAB COMPARED WITH ADALIMUMAB
https://doi.org/10.1136/annrheumdis-2019-eular.3294
Documents that mention this clinical trial
SAT0212 Sarilumab dose reduction in an open-label extension study in ra patients with inadequate response to tnf inhibitors
https://doi.org/10.1136/annrheumdis-2017-eular.5155
THU0215 Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab
https://doi.org/10.1136/annrheumdis-2018-eular.1376
SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
https://doi.org/10.1136/annrheumdis-2019-eular.245
FRI0092 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TUMOR NECROSIS FACTOR INHIBITORS
https://doi.org/10.1136/annrheumdis-2020-eular.1946
SAT0172 Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csdmards in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.1373
FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS
https://doi.org/10.1136/annrheumdis-2019-eular.740
SAT0106 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH 1 OR >1 PRIOR TUMOR NECROSIS FACTOR INHIBITOR FAILURES
https://doi.org/10.1136/annrheumdis-2020-eular.332
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
https://doi.org/10.1136/rmdopen-2018-000887
Funding for this research was provided by:
Regeneron Pharmaceuticals
Sanofi Genzyme